Esketamine

Esketamine’s modern psychiatric story sits on top of ketamine’s longer trajectory. Ketamine was synthesised in the early 1960s as a phencyclidine-related arylcyclohexylamine intended to preserve anaesthesia while reducing the prolonged delirium of PCP, and it became widely used in human and veterinary medicine as a dissociative anaesthetic. Contemporary policy reviews continue to frame ketamine (and its enantiomers) as clinically valuable but also subject to substantial harms under chronic high-dose non-medical use.

In the United States, ketamine (including its salts and isomers) was placed into Schedule III of the Controlled Substances Act in 1999, reflecting recognised medical uses alongside misuse liability; this legal status shaped subsequent clinical research by requiring controlled-substance handling without imposing the near-total restrictions associated with Schedule I.

The antidepressant renaissance began with small, controlled human studies of sub-anaesthetic ketamine showing rapid symptom improvement in depression. Early clinical reports (for example, Berman and colleagues, 2000, and later Zarate and colleagues at the US National Institute of Mental Health in 2006) catalysed two parallel lines of work: mechanistic exploration of glutamatergic and synaptic-plasticity pathways, and translational efforts to develop products and service models capable of delivering ketamine-class treatments safely and reproducibly.

Esketamine emerged as the most commercially tractable enantiomer to pursue within a regulated pharmaceutical framework, in part because stereoselective differences in NMDA receptor affinity and potency provided a plausible rationale for dose optimisation and because intranasal delivery offered a practical outpatient route. Janssen’s development programme received FDA Breakthrough Therapy Designation for TRD in November 2013 and a second Breakthrough Therapy Designation for major depressive disorder with imminent risk for suicide in August 2016, reflecting preliminary evidence of rapid antidepressant and anti-suicidal-symptom effects.

Methodological sophistication has advanced markedly across the subsequent decade. Esketamine programmes evolved from short-term symptom-change endpoints to include relapse-prevention (randomised withdrawal) designs, long-term open-label exposure datasets, and tightly specified risk-minimisation systems. By 2025, the US label had expanded to allow TRD monotherapy, a notable regulatory shift that may reduce friction for some patients and address real-world discontinuation driven by tolerability or preference regarding concomitant oral antidepressants.

Primary psychoactive pharmacology for esketamine is dominated by non-competitive antagonism at the N-methyl-D-aspartate (NMDA) receptor. Esketamine is the S(+)-enantiomer of ketamine and shows higher affinity at the NMDA receptor binding site than arketamine (R(-)-ketamine), a stereochemical difference often described as translating into higher anaesthetic and analgesic potency and helping to explain why esketamine was advanced as a distinct medicinal product.

The antidepressant mechanism is not established. A widely supported working model, derived largely from ketamine research, proposes that transient NMDA receptor blockade—especially on inhibitory interneurons—produces short-lived disinhibition and a glutamatergic surge, which increases AMPA receptor throughput and triggers synaptic-plasticity programmes (including BDNF-linked and mTOR-linked signalling). These downstream changes are hypothesised to reverse stress-associated synaptic deficits in prefrontal–limbic circuits and thereby produce symptom relief that can outlast acute intoxication.

Esketamine is not pharmacologically ‘single-target’. Policy syntheses and mechanistic reviews emphasise actions beyond NMDA receptor antagonism, including measurable affinity for the mu-opioid receptor and interactions with monoamine transporters and other receptor systems. The extent to which these non-NMDA actions contribute to antidepressant response in humans is unresolved; they are, however, plausible contributors to the acute dissociative state, autonomic effects, and reinforcement liability that drive the need for controlled delivery.

For intranasal administration, pharmacokinetics are specified in regulatory labelling. Absolute bioavailability is approximately 48%, with peak plasma concentrations typically reached 20–40 minutes after the last spray; the FDA label notes this timing corresponds to Cmax for monitoring purposes. Exposure increases are slightly more than dose-proportional across 28 mg, 56 mg and 84 mg. Esketamine is moderately protein bound (approximately 43%–45%), has a large apparent volume of distribution, and exhibits a terminal half-life of roughly 7–12 hours, supporting intermittent dosing rather than daily self-administration.

Metabolism is largely hepatic. Esketamine is mainly metabolised via CYP2B6 and CYP3A4, with additional contribution from CYP2C9 and CYP2C19, through N-demethylation to noresketamine followed by hydroxylation and conjugation to multiple metabolites. The major circulating metabolite noresketamine is described as less potent at the NMDA receptor than the parent compound, and less than 1% of dose is excreted unchanged in urine. In clinical terms, meaningful psychoactive exposure is concentrated in the early post-dose window rather than being driven by slow conversion to long-lived active metabolites.

Route, administration context and dose–response are inseparable for esketamine’s psychiatric use. Each intranasal device delivers 28 mg across two sprays; a typical treatment session therefore delivers 56 mg (two devices) or 84 mg (three devices). In EU product information, TRD treatment begins with an induction phase (56 mg on day 1, then 56 mg or 84 mg twice weekly for weeks 1–4) followed by reduced-frequency maintenance tailored to the lowest frequency that maintains response; for psychiatric emergency due to MDD, the EU label specifies a short, intensive 4-week course at 84 mg twice weekly with dose reduction to 56 mg based on tolerability. These schedules co-evolved with monitoring requirements because the acute dissociative and haemodynamic effects are dose-related and temporally clustered after dosing.

Biomarker and neuroimaging findings remain more mature for intravenous racemic ketamine than for intranasal esketamine, but the mechanistic hypothesis space overlaps. Neuroimaging studies with ketamine in depression implicate rapid shifts in fronto-limbic processing and large-scale network dynamics as candidate mediators of symptom change; contemporary syntheses argue that these systems-level effects offer the most plausible bridge between receptor pharmacology and clinical outcomes. It remains unclear which biomarker signatures (molecular, electrophysiological, or network-level) will generalise robustly enough to guide esketamine patient selection or dosing frequency in routine care.

Across controlled trials, the acute tolerability profile of intranasal esketamine is characterised by time-limited neuropsychiatric and autonomic effects that are most prominent in the first hours after dosing. For TRD, adverse reactions occurring at ≥2% and more frequently than placebo included nausea (25% vs 8%), vomiting (7% vs <1%), feeling drunk (7% vs <1%) and blood pressure increased (5% vs 2%), alongside vestibular and perceptual symptoms such as vertigo. In the MDD with acute suicidal ideation or behaviour programme, dissociation (48% vs 13%), dizziness (45% vs 15%), sedation (29% vs 12%) and blood pressure increased (15% vs 6%) were prominent. These effects commonly peak near Cmax and are the immediate reason the product is delivered only in supervised healthcare settings.

Cardiovascular and cerebrovascular risk management is central. Esketamine can cause clinically meaningful increases in blood pressure; the FDA label recommends reassessment at approximately 40 minutes post-dose (corresponding with Cmax) and continued monitoring until values decline, with emergency evaluation for symptoms suggestive of hypertensive crisis or hypertensive encephalopathy. Spravato is contraindicated in patients for whom blood-pressure or intracranial-pressure increases pose serious risk, including aneurysmal vascular disease or arteriovenous malformation, and in those with a history of intracerebral haemorrhage. EU product information similarly specifies baseline blood-pressure assessment and post-dose reassessment at around 40 minutes, and it directs that prescribing be determined by a psychiatrist with treatment delivered in an appropriate clinical setting.

Sedation, dissociation and cognitive effects are operationally managed as predictable, time-limited phenomena. In clinical trials, 48%–61% of esketamine-treated patients developed sedation based on the Modified Observer’s Assessment of Alertness/Sedation scale. The label describes short-term cognitive impairment peaking at around 40 minutes post-dose in healthy volunteers, and it includes dedicated on-road driving studies; as a result, patients are counselled not to drive or operate machinery until the next day after a restful sleep. Respiratory depression is a recognised risk: the FDA label notes that patients may display diminished or less apparent breathing during sedation and that post-marketing cases of respiratory depression have been reported.

Abuse potential and dependence liability are treated as clinically salient, reflecting both ketamine’s history as a drug of misuse and esketamine’s own subjective effects. In the US, esketamine is handled as a Schedule III controlled substance and the label warns of abuse and misuse. FDA reviews report that, in the human abuse potential study in non-dependent recreational polydrug users (N=34), intranasal esketamine produced significantly greater ratings of drug liking than placebo and a signal comparable to intravenous ketamine, supporting the need for restricted distribution and monitoring. In the UK, additional diversion-control measures have been implemented; for example, MHRA-agreed communications describe a Register and Alert System for esketamine intended to mitigate abuse and diversion risk.

Clinically significant drug–drug interactions are primarily expected via additive sedation and haemodynamic effects rather than strong pharmacokinetic inhibition or induction. The FDA label advises close monitoring when esketamine is used concomitantly with central nervous system depressants (owing to sedation) and with psychostimulants or monoamine oxidase inhibitors (MAOIs) due to blood-pressure elevation. Conversely, esketamine has been studied and routinely used alongside SSRIs and SNRIs, which remain the default oral antidepressant partners under EU and UK indications. With lithium, the evidence base is thinner: lithium augmentation is a standard TRD step in some care pathways, and it featured as an important comparator backdrop in health-technology appraisal work, but there is no labelled pharmacokinetic interaction and it remains unclear whether lithium meaningfully alters esketamine efficacy or tolerability in routine practice; careful clinical monitoring is therefore prudent when combining treatments in complex TRD regimens.

Risk minimisation infrastructure is extensive and materially shapes real-world implementation. In the US, Spravato is available only through the Spravato REMS, which requires enrolment, administration under direct observation, and at least 2 hours of monitoring post-dose before discharge if clinically stable. In Canada, Health Canada’s decision materials describe a Controlled Distribution Program designed to manage sedation, dissociation, hypertension, and abuse/diversion risk through enrolment of prescribers, pharmacies and patients, supervised self-administration, and controlled product delivery to the site of care. EU product information similarly requires supervised administration and post-dose monitoring, and UK materials additionally include diversion mitigation via registry systems.

The pivotal evidence base for psychiatric use of esketamine is built around Janssen’s multi-study Phase III programme in TRD and in acute suicidal presentations, supplemented by long-term open-label extensions. In the FDA label’s primary short-term TRD efficacy study (Study 1; NCT02418585), adults with TRD were randomised to intranasal esketamine (56 mg or 84 mg) plus a newly initiated oral antidepressant versus placebo nasal spray plus oral antidepressant for 4 weeks; the primary endpoint was MADRS change at Week 4 and favoured esketamine (least-squares mean difference -4.0; 95% CI -7.3 to -0.6). Health Canada’s decision summary notes that, across the Phase III short-term TRD programme, the flexible-dose adult study was statistically significant while the fixed-dose study showed suggestive but sequence-limited results, and efficacy was not demonstrated in the elderly short-term study, illustrating heterogeneity across designs and populations.

Durability of benefit has been explicitly tested using withdrawal design. In the relapse-prevention trial (Study 2; NCT02493868), patients who achieved stable response or stable remission on esketamine plus oral antidepressant were randomised to continue esketamine or switch to placebo nasal spray while maintaining the oral antidepressant. Continuing esketamine delayed relapse; the FDA label reports hazard ratios of 0.30 (stable responders) and 0.49 (stable remitters), while also noting that the hazard ratio did not appear constant throughout the trial.

A notable recent development is the TRD monotherapy dataset. In Study 3 (NCT04599855), patients who discontinued prior antidepressants as applicable received esketamine 56 mg, esketamine 84 mg, or placebo nasal spray twice weekly for 4 weeks as monotherapy. Both doses separated from placebo on the Day 28 MADRS endpoint (least-squares mean differences -5.1 and -6.8). This programme underpins the US indication permitting TRD monotherapy.

For acute presentations, the FDA label describes two identical Phase III studies in adults with moderate-to-severe MDD and acute suicidal ideation with intent (Study 4; NCT03039192 and Study 5; NCT03097133). Patients received comprehensive standard of care (including initial inpatient psychiatric hospitalisation and a newly initiated or optimised oral antidepressant) plus esketamine 84 mg or placebo nasal spray twice weekly for 4 weeks. The primary endpoint—MADRS change at 24 hours after first dose—was met in both studies (least-squares mean differences -3.8 and -3.9), while the key suicidality-related secondary measure (CGI-SS-r) did not separate from placebo.

Long-term safety and implementation-relevant questions (maintenance frequency, cumulative exposure, sustained response) are addressed mainly in open-label extensions. Wajs and colleagues reported up to 1-year data for esketamine plus oral antidepressant in TRD (SUSTAIN-2; NCT02497287). Zaki and colleagues reported interim SUSTAIN-3 findings and subsequent long-term updates indicating no new safety signal with intermittent dosing over multi-year exposure (reported up to 4.5 years). EU product information and trial registry materials describe the Phase III extension study TRD3008 enrolling 1,148 adults with TRD.

Beyond the registration programme, esketamine is being explored in adjacent populations under controlled conditions. Examples include adolescent severe-depression or suicidality research (Kosik-Gonzalez and colleagues, 2026) and small investigator-initiated studies in bipolar depression (for example, an EU Clinical Trials Information System listing for therapy-resistant bipolar depression). These streams remain exploratory relative to the mature TRD evidence base and have not yet set a stable regulatory path for additional indications.

TRD remains the clearest clinical use case, supported by multiple Phase III trials, relapse-prevention evidence, and growing multi-year exposure datasets. The practical niche is for adults with established non-response to at least two adequate antidepressant trials, particularly where symptom burden is high and clinicians prioritise rapid symptom reduction and functional stabilisation. In real-world delivery, the unmet need is often less whether it works than how to deliver it: clinic throughput, observation capacity, and patient acceptability of repeated supervised visits are major determinants of impact. Both FDA and EU labelling emphasise periodic reassessment of benefit and individualisation of maintenance frequency to the lowest frequency that maintains response.

The evidence base for acute suicidal presentations is best understood as demonstrating rapid reduction in depressive symptoms in the context of comprehensive standard of care rather than a proven anti-suicidal effect. In the two pivotal Phase III studies in adults with MDD and acute suicidal ideation with intent, esketamine improved MADRS scores at 24 hours but did not improve a clinician-rated suicidality severity score (CGI-SS-r) relative to placebo. This creates a clinically important boundary: esketamine may help reduce depressive symptom intensity quickly, but it remains unclear whether it reduces suicidal behaviour, and it should be conceptualised as an adjunct within a broader crisis-care pathway rather than a stand-alone suicide-prevention intervention.

The US monotherapy indication for TRD is likely to influence near-term practice patterns. For some patients, the earlier requirement to initiate or continue an oral antidepressant was a barrier (prior intolerability, preference, or non-adherence). The monotherapy dataset demonstrates a short-term antidepressant signal over 4 weeks, but the strongest durability evidence and relapse-prevention data remain anchored in combination-therapy programmes. A key next step is therefore rigorous evaluation of whether monotherapy can sustain response over months, what maintenance frequency is required, and whether monotherapy meaningfully changes tolerability or discontinuation rates compared with combination strategies.

Several emerging applications are attracting research attention but remain earlier-stage than TRD. The literature includes adolescent studies in severe depression with acute suicidal risk (with efficacy signals on depressive symptoms) and investigator-initiated trials in therapy-resistant bipolar depression. These areas face added clinical and regulatory hurdles, including heightened uncertainty around dissociation and abuse-liability in younger populations and the need for robust mood-switch monitoring in bipolar disorder, as well as the challenge of demonstrating durable benefit beyond short-term symptom change.

Methodologically, next-generation studies are likely to emphasise comparative and pathway-optimisation designs: head-to-head comparisons against other high-intensity interventions (for example, rTMS, ECT, and structured ketamine infusion programmes), refinement of dosing frequency using longitudinal symptom dynamics, and implementation science that clarifies how to integrate supervised dosing into mental-health systems at scale. Comparative effectiveness evidence is emerging (including analyses comparing intranasal esketamine with rTMS), but it remains too early to claim a stable hierarchy across modalities because patient selection, service intensity, and outcome definitions differ markedly across trials and health systems.

United States: intranasal esketamine is authorised for adults with TRD (as monotherapy or with an oral antidepressant) and for depressive symptoms in adults with MDD with acute suicidal ideation or behaviour (with an oral antidepressant and comprehensive standard of care). The product is a federally controlled substance and must be handled as Schedule III; it is also available only through the Spravato REMS, requiring administration under direct observation and at least 2 hours of post-dose monitoring before discharge when clinically stable.

United Kingdom: ketamine is listed as a Class B drug under the Misuse of Drugs Act 1971 and Schedule 2 under the Misuse of Drugs Regulations 2001; the controlled-drugs list explicitly notes that, where stated in legislation, stereoisomers are also controlled, which is the relevant framework for esketamine as a ketamine stereoisomer. The UK Summary of Product Characteristics for Spravato positions intranasal esketamine in combination with an SSRI or SNRI for TRD, under psychiatrist prescribing and supervised administration. NICE has not recommended esketamine nasal spray within its technology appraisal scope, and the MHRA has supported additional diversion safeguards via registry requirements.

European Union: Spravato is centrally authorised with indications for TRD (in combination with an SSRI or SNRI) and for acute short-term treatment for rapid reduction of depressive symptoms in a moderate-to-severe MDD episode that constitutes a psychiatric emergency in clinical judgement. The EU product information requires psychiatrist-determined prescribing, supervised self-administration, and post-dose observation, including blood-pressure reassessment at around 40 minutes. Controlled-drug handling requirements are implemented through Member State legislation rather than an EU-wide scheduling system, so practical restrictions vary by jurisdiction despite central authorisation.

Australia: intranasal esketamine (Spravato) is registered on the Australian Register of Therapeutic Goods (ARTG), with TGA decision and registration dates in March 2021. Across Australia, ketamine and esketamine are classified as Schedule 8 (‘Controlled Substance’) in the Poisons Standard, which imposes additional prescribing and storage requirements. Reimbursement decisions are separate from registration; policy commentary indicates that funding and listing decisions have been a key determinant of real-world access since registration.

Canada: Health Canada granted marketing authorisation on 2020-05-20 for Spravato in combination with an SSRI or SNRI for adults with MDD who have not responded adequately to at least two antidepressant courses in the current episode, and the decision documentation describes a Risk Management Plan and Controlled Distribution Program with enrolment and supervised administration requirements. In parallel, ketamine is controlled under Schedule I of the Controlled Drugs and Substances Act in Canada, reflecting a stringent controlled-substance environment even alongside legitimate medical use.

Forward regulatory pathways are most plausible as indication expansions rather than first approvals. In the US, this typically means a supplemental New Drug Application supported by additional Phase II/Phase III efficacy and safety evidence (and potentially post-marketing commitments focused on abuse/diversion, respiratory safety, or long-term cognition). In the EU, analogous changes generally proceed via a Type II variation to the marketing authorisation with updated risk-management planning. Timelines for new indications are likely multi-year and contingent on sustained evidence of benefit that is both clinically meaningful and operationally deliverable under controlled-substance safeguards.

The commercial narrative for esketamine is overwhelmingly defined by Johnson & Johnson’s Janssen franchise and the Spravato intranasal delivery platform. Strategically, intranasal delivery and intermittent clinic-based dosing differentiate Spravato from the fragmented off-label racemic ketamine infusion market by pairing a patented device/formulation with regulatory-grade Phase III evidence and payer-visible risk controls. This is reflected in financial disclosures: Johnson & Johnson reports Spravato 2025 worldwide sales of $1,696m (Q4: $503m), indicating sustained demand growth for a rapid-acting glutamatergic antidepressant despite operational constraints.

Commercial scalability is constrained by delivery economics. The product must not be dispensed for home use; administration occurs under direct observation with post-dose monitoring and controlled-substance handling. Clinics therefore require certified processes, vital-sign monitoring capacity, and recovery space, with staffing capable of managing dissociation, sedation, and blood-pressure elevations. These requirements create a high fixed-cost service model that tends to concentrate delivery in specialised centres and favours reimbursement environments that can price and pay for the combined drug-plus-service bundle.

Label evolution and reimbursement dynamics are major value drivers. The 2025 US monotherapy indication for TRD broadens the eligible pool to patients who cannot tolerate, or are unwilling to take, concomitant oral antidepressants and may simplify prescribing for clinicians who view medication switching as destabilising in severe TRD. However, country-level funding decisions remain pivotal: in the UK, NICE non-recommendation has restrained NHS uptake within the appraisal scope; in Australia, registration occurred in 2021 under an S8 controlled-substance framework, and subsequent policy developments around public subsidy have been treated as a key determinant of real-world access.

From an innovation and IP perspective, near-term differentiation is more likely to come from implementation refinements than from new chemistry within esketamine itself: optimisation of dosing frequency, stratified patient selection, and clinic workflow innovations that reduce patient time on site while maintaining safety. Longer-term, the growth of the rapid-acting antidepressant market is likely to be shaped by adjacent and competing assets rather than incremental Spravato formulation changes, particularly as multiple groups pursue ketamine-related or glutamatergic mechanisms with different routes and monitoring burdens.

The most strategically relevant competition involves either cheaper ketamine service models or next-generation ketamine analogues that aim for similar efficacy with fewer dissociative effects or easier delivery. Intravenous racemic ketamine remains widely used off-label, and regulatory communications have highlighted safety concerns with compounded ketamine products used for psychiatric indications. On the pipeline side, arketamine programmes (for example, Perception Neuroscience/atai’s PCN-101; NCT05414422) illustrate an attempt to compete on tolerability and potentially more flexible delivery models, though clinical efficacy remains under active evaluation and has not yet established a clear regulatory pathway.

Within dissociative rapid-acting antidepressant approaches, the most relevant comparator is racemic ketamine (a 50: 50 mixture of esketamine and arketamine) delivered intravenously or intramuscularly in off-label service models. Esketamine is the S(+)-enantiomer and has higher NMDA receptor affinity than arketamine; racemic ketamine exposes patients to both enantiomers and therefore cannot be assumed to be pharmacodynamically equivalent to esketamine session-for-session. From an evidence standpoint, intranasal esketamine has a large, regulator-reviewed Phase III dataset in TRD and a defined product label, whereas ketamine in psychiatry is largely delivered off-label and its regulatory status differs by indication.

Delivery governance often matters more than subtle receptor pharmacology. Spravato operates as a drug-plus-service model: in the US it is tied to a REMS that prohibits home dispensing and requires direct observation with at least 2 hours of monitoring, and in Canada decision documents describe a Controlled Distribution Program with enrolment and supervised administration structures. This standardisation is a differentiator for payers and regulators, but it raises implementation barriers (trained staff, recovery space, and monitoring infrastructure) and increases the cost of each treatment session.

Arketamine is emerging as an additional comparator with strategic relevance. Mechanistic reviews frequently hypothesise that arketamine might retain antidepressant effects with fewer dissociative symptoms, but current human evidence remains preliminary and has not established a reliable clinical advantage over esketamine. Clinical development is ongoing; for example, PCN-101 (R-ketamine) is being evaluated in treatment-resistant depression in a randomised, placebo-controlled study (NCT05414422).

Against non-pharmacological, high-intensity comparators such as repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT), esketamine’s differentiating value is rapid onset via glutamatergic mechanisms; its limiting factors are dissociation, haemodynamic effects, and the clinic-time burden. Comparative effectiveness work is emerging (including analyses that place intranasal esketamine and rTMS on a common depression-severity scale), but stable ranking across modalities remains premature because treatment intensity, patient selection, and ancillary care differ across studies and health systems.